A Multicenter, Randomized, Placebo-controlled, Double-blind, 26 Week Study to Evaluate the Efficacy and Safety of Amantadine HCl Extended Release Tablets in Parkinson's Disease Subjects With Levodopa-Induced Dyskinesias

Trial Profile

A Multicenter, Randomized, Placebo-controlled, Double-blind, 26 Week Study to Evaluate the Efficacy and Safety of Amantadine HCl Extended Release Tablets in Parkinson's Disease Subjects With Levodopa-Induced Dyskinesias

Recruiting
Phase of Trial: Phase III

Latest Information Update: 05 Aug 2016

At a glance

  • Drugs Amantadine (Primary)
  • Indications Drug-induced dyskinesia
  • Focus Registrational; Therapeutic Use
  • Acronyms ALLAY-LID II
  • Sponsors Osmotica Pharmaceutical
  • Most Recent Events

    • 18 Jun 2016 This trial was Temporarily Halted in Spain.
    • 09 Feb 2016 Planned End Date changed from 1 Dec 2015 to 1 Nov 2016 as reported by ClinicalTrials.gov record.
    • 09 Feb 2016 Planned primary completion date changed from 1 Nov 2015 to 1 Sep 2016 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top